In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Iovance Biotherapeutics (IOVA – Research Report). The company’s shares closed yesterday at $6.07.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and Madrigal Pharmaceuticals (MDGL – Research Report).

It was about a year ago that shares of Iovance Biotherapeutics (NASDAQ: IOVA) began to take off. The stock soared on news of approval from the Food and Drug Administration for Amtagvi (lifileucel ...

Iovance Biotherapeutics (NASDAQ: IOVA), a small-cap biotech company, has an innovative approach to treating cancer that relies on harnessing patients' cancer-fighting capabilities. Though the ...

One company Wall Street analysts have set their sights on, Iovance Biotherapeutics (NASDAQ: IOVA), is pioneering a new approach to treating cancer. Outstanding clinical trial results pushed this ...

Shares of Iovance Biotherapeutics have been nosediving in recent months. Despite Amtagvi's approval, investors appear concerned with Iovance's financials. The biotech has been burning through cash ...

Iovance's leading candidate should make regulatory progress in the next five years. The biotech company's pipeline could also make exciting breakthroughs. Its stock could have substantial upside ...

Stifel maintains Buy on Iovance stock with $21 target On Monday, Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to ...

As of January 28 at 1:30:19 PM EST. Market Open.

UBS has recently initiated Iovance Biotherapeutics Inc (IOVA) stock to Buy rating, as announced on October 24, 2024, according to Finviz. Earlier, on July 29, 2024, Piper Sandler had reduced the stock ...